Who are Tafamidis (Reference)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyndaqel, Alomide, Alocril, CROMOLYN SODIUM, Intal, Lithobid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tafamidis-reference.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tafamidis (Reference) — Competitive Intelligence Brief

Tafamidis (Reference) (tafamidis-reference) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Stabilizer. Area: Neuroscience.

marketed Stabilizer TTR protein Neuroscience Live · refreshed every 30 min

Target snapshot

Tafamidis (Reference) (tafamidis-reference) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tafamidis (Reference) TARGET	tafamidis-reference	Pfizer	marketed	Stabilizer	TTR protein
Vyndaqel	Tafamidis Meglumine	Foldrx Pharms	marketed	Transthyretin stabilizer	Transthyretin (TTR)	2019-01-01
Alomide	LODOXAMIDE	Novartis	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1993-01-01
Alocril	NEDOCROMIL	AbbVie	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1992-01-01
CROMOLYN SODIUM	CROMOLYN SODIUM		marketed	Mast cell stabilizer	Mast cells	1982-01-01
Intal	cromoglicic acid	Pfizer	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1982-01-01
Lithobid	lithium carbonate	Generic (multiple manufacturers)	marketed	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Stabilizer class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tafamidis (Reference) — Competitive Intelligence Brief. https://druglandscape.com/ci/tafamidis-reference. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab